These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
116 related articles for article (PubMed ID: 9256894)
1. Mitoxantrone in the treatment of metastatic transitional cell carcinoma of the prostate. A case report. Stewart DJ; Dahrouge S Am J Clin Oncol; 1997 Aug; 20(4):381-2. PubMed ID: 9256894 [TBL] [Abstract][Full Text] [Related]
2. Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. Saxman SB; Propert KJ; Einhorn LH; Crawford ED; Tannock I; Raghavan D; Loehrer PJ; Trump D J Clin Oncol; 1997 Jul; 15(7):2564-9. PubMed ID: 9215826 [TBL] [Abstract][Full Text] [Related]
3. Is the use of anything but MVAC justified in the evidence-based medicine era? Ok JH; Cambio A; Lara PN; Evans CP Curr Opin Urol; 2005 Sep; 15(5):312-4. PubMed ID: 16093854 [No Abstract] [Full Text] [Related]
4. Primary transitional cell carcinoma of prostate: case with lymph node metastasis eradicated by neoadjuvant methotrexate, vinblastine, doxorubicin, and cisplatin (M-VAC) therapy. Takashi M; Sakata T; Nagai T; Kato T; Sahashi M; Koshikawa T; Miyake K Urology; 1990 Jul; 36(1):96-8. PubMed ID: 2368239 [TBL] [Abstract][Full Text] [Related]
5. A randomized phase II trial of echinomycin, trimetrexate, and cisplatin plus etoposide in patients with metastatic nonsmall cell lung carcinoma: an Eastern Cooperative Oncology Group Study (E1587). Chang AY; Kim K; Boucher H; Bonomi P; Stewart JA; Karp DD; Blum RH Cancer; 1998 Jan; 82(2):292-300. PubMed ID: 9445185 [TBL] [Abstract][Full Text] [Related]
6. Usefulness and limitations of methotrexate, vinblastine, doxorubicin and cisplatin for the treatment of advanced urothelial cancer. Igawa M; Ohkuchi T; Ueki T; Ueda M; Okada K; Usui T J Urol; 1990 Sep; 144(3):662-5. PubMed ID: 2388322 [TBL] [Abstract][Full Text] [Related]
7. [Usefulness of magnetic resonance imaging for evaluation of therapeutic efficacy of bone metastases from bladder cancer: a case report]. Urushibara M; Tsukamoto T; Horiuchi S; Negishi T Hinyokika Kiyo; 1998 Jul; 44(7):501-3. PubMed ID: 9752607 [TBL] [Abstract][Full Text] [Related]
8. M-VEC (methotrexate, vinblastine, epirubicin, and cisplatin) with granulocyte colony-stimulating factor for the treatment of urothelial cancer: an effective and safe chemotherapy regimen. Igawa M; Kadena H; Ueda M; Usui T Cancer Chemother Pharmacol; 1994; 35 Suppl():S1-4. PubMed ID: 7527732 [TBL] [Abstract][Full Text] [Related]
9. Complete responses in metastatic transitional cell carcinoma of the prostate with cisplatin regimens. Dexeus FH; Logothetis CJ; Samuels ML; Ayala AG; Hossan E J Urol; 1987 Jan; 137(1):122-5. PubMed ID: 3795354 [TBL] [Abstract][Full Text] [Related]
10. Phase I trial of paclitaxel, carboplatin, and methotrexate with granulocyte colony-stimulating factor and leucovorin in advanced transitional cell carcinoma. Edelman MJ; Meyers FJ; Houston J; Lauder I Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-68-S15-71. PubMed ID: 9346226 [TBL] [Abstract][Full Text] [Related]
11. Vinorelbine and cisplatin (CIVIC regimen) for the treatment of metastatic breast carcinoma after failure of anthracycline- and/or paclitaxel-containing regimens. Ray-Coquard I; Biron P; Bachelot T; Guastalla JP; Catimel G; Merrouche Y; Droz JP; Chauvin F; Blay JY Cancer; 1998 Jan; 82(1):134-40. PubMed ID: 9428489 [TBL] [Abstract][Full Text] [Related]
12. Impact of surgical resection of bladder cancer metastases refractory to systemic therapy on performance score: a phase II trial. Otto T; Krege S; Suhr J; Rübben H Urology; 2001 Jan; 57(1):55-9. PubMed ID: 11164143 [TBL] [Abstract][Full Text] [Related]
16. Treatment of chemotherapy-refractory metastatic urothelial tumors. Logothetis C Urol Clin North Am; 1992 Nov; 19(4):775-7. PubMed ID: 1441031 [TBL] [Abstract][Full Text] [Related]
17. Prolonged remission in a patient with transitional cell carcinoma of the bladder developing brain metastases after systemic chemotherapy: a case report. Jankevicius F; Sruogis A; Ulys A; Zykus A; Sumauskas R Tumori; 2004; 90(4):420-1. PubMed ID: 15510987 [TBL] [Abstract][Full Text] [Related]
18. [A case of metastatic carcinoma of the duodenum from bladder]. Kanemasa H; Kodama T; Nakajima M; Sawai N; Tanahashi T; Tokita K; Mitsufuji S; Kashima K; Nakagawa S; Watanabe H; Tsuchihashi Y Nihon Shokakibyo Gakkai Zasshi; 1997 Oct; 94(10):676-80. PubMed ID: 9391330 [No Abstract] [Full Text] [Related]
19. Phase II trial of intermediate dose methotrexate in combination with vinblastine, doxorubicin, and cisplatin in patients with unresectable or metastatic transitional cell carcinoma. Dodd PM; McCaffrey JA; Mazumdar M; Scher H; Vlamis V; Higgins G; Herr H; Bajorin DF Cancer; 1999 Mar; 85(5):1145-50. PubMed ID: 10091800 [TBL] [Abstract][Full Text] [Related]
20. Methotrexate, vinblastine, adriamycin and cisplatin (MVAC) chemotherapy for the treatment of advanced bladder carcinoma. Balbay MD; Ozen H; Uluçay S; Sahin A; Ergen A; Koçal C; Remzi D Int Urol Nephrol; 1993; 25(4):351-7. PubMed ID: 8276565 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]